CSI Market
Sign In | Register

Owc Pharmaceutical Research (OWCP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access OWCP Annual Cash Flow →
Looking at cash flow data from Owc Pharmaceutical Research through Sep 30 2018 provides insight into Sep 30 2019's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2019)
9 Months 		(Jun 30 2019) (Mar 31 2019) (Dec 31 2018) (Sep 30 2018)
Operating Activities
Income6.42
Depreciation & amortization0.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.14
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Amortization Of Debt Discount-
Common Stock Issued For Services-
Accounts Payable Related Party-
Derivative Valuation Adjustments-
Common Stock Issued For Services-
Fair Value Of Options And Warrants Issued For Services-
Advances And Accounts Payable Related Parties-
Increase Decrease Accounts Receivable Related Party-
Increase Decrease In Accounts Receivable Related Party-
Increase Decrease In Accounts Payable Related Party-
Exchange Differences On Principal Of Long Term Loan-
Temporary Equity Foreign Currency Translation Adjustments-
Adjustments To Convertible Loans-
Depreciation Expense-
Revaluation Of Liability Related To Warrant To Purchase Common Stock-1.36
Embedded Derivative Gain Loss On Embedded Derivative Net0.05
Lease Liabilities Increase Decrease-0.02
Lease Rightofuse Assets Increase Decrease0.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.19
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Increase (Decrease) in Customer Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital-0.25
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-7.19
Discontinued operations0.00
Net Cash flow from Operating Activities-1.99
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds Of Debt Borrowings-
Related Party Advances-
Principal Payments-
Foreign Currency Translations-
Debt Instrument Periodic Payment Principal-
Foreign Currency Exchange Rate Translation-
Foreign Currency Translation-
Foreign Currency Translation-
Proceeds Of Nonrecourse Loan-
Payment Of Nonrecourse Loan-
Proceeds From Collection Of Subscription Receivable-
Proceeds From Payment Received On Stock Subscriptions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-1.99
Total Cash Flow-2.00
4 historic quarters locked

Sign in to unlock the full Owc Pharmaceutical Research cash flow history.

Sign In Create Free Account

About OWCP Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Get the full CSIMarket dataset: Subscribe API License